Abstract
Certain form of aptamers have ability to bind proteins including surface proteins. These aptamers are capable of binding active region of the proteins, helping treatment of many diseases. Their stability and high binding affinity equivalent to the antibodies makes them a strong candidate for the protein targeting for the purpose of diagnosis, new drug discovery and therapy. They can be used for targeting of protein of wide range of organism like viruses, bacteria or cells from any other organism. Protein targeting by aptamers also have potential in proteomics where studies of large number of proteins becomes an absolute necessity. With the increase in understanding of aptamers and protein interaction new therapeutic strategies will evolve and benefit the mankind.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berezovski M, Drabovich A, Krylova SM, Musheev M, Okhonin V, Petrov A, Krylov SN (2005) Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J Am Chem Soc 127:3165–3171
Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J et al (2010) Antibody validation. BioTechniques 48:197–209
Doudna JA, Cech TR et al (1995) Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci U S A 92:2355–2359
Javaherian S, Musheev MU, Kanoatov M, Berezovski MV, Krylov SN (2009) Selection of aptamers for a protein target in cell lysate and their application to protein purification. Nucleic Acids Res 37(8):e62
Lee SW, Sullenger BA (1997) Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 15:41–45
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123–132
Perkel JM (2014) The antibody challenge. BioTechniques 56:111–114
Raddatz MS, Dolf A, Endl E, Knolle P, Famulok M, Mayer G (2008) Enrichment of cell-targeting and populationspecific aptamers by fluorescence-activated cell sorting. Angew Chem Int Ed 47:5190–5193
Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ (2015) Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation. Mol Oncol 9(7):1392–1405
Rugo HS (2004) Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9(Suppl):43–49
Rusconi CP, Yeh A et al (2000) Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 84:841–848
Rusconi CP, Scardino E et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90–94
Savory N, Takahashi Y, Tsukakoshi K, Hasegawa H, Takase M, Abe K, Yoshida W, Ferri S, Kumazawa S, Sode K, Ikebukuro K (2014 Mar) Simultaneous improvement of specificity and affinity of aptamers against Streptococcus mutans by in silico maturation for biosensor development. Biotechnol Bioeng 111(3):454–461
Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y et al (2013) RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330(1):84–95.
Sullenger BA, Gallardo HF, Ungers GE, Gilboa E (1990) Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63(3):601–608
Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P, Chen HW, Li Y, Tan W (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79(13):4900-7. Epub 2007 May 27
White RR, Sullenger BA et al (2000) Developing aptamers into therapeutics. J Clin Invest 106:929–934
Wochner A, Menger M, Orgel D, Cech B, Rimmele M, Erdmann VA, Glokler J (2008) A DNA aptamer with high affinity and specificity for therapeutic anthracyclines. Anal Biochem 373:34–42
Zeng Z, Zhang P, Zhao N, Sheehan AM, Tung CH, Chang CC et al (2010) Using oligonucleotide aptamer probes for immunostainingof formalin-fi xed and paraffi n-embedded tissues. Mod Pathol 23:1553–1558
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kumar, V., Banerjee, H. (2019). Current Development and Future Prospects of Aptamer Based Protein Targeting. In: Yadav, G., Kumar, V., Aggarwal, N. (eds) Aptamers. Springer, Singapore. https://doi.org/10.1007/978-981-13-8836-1_8
Download citation
DOI: https://doi.org/10.1007/978-981-13-8836-1_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8835-4
Online ISBN: 978-981-13-8836-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)